WASHINGTON, DC (February 14, 2022) — The Board of Directors of the Association for Accessible Medicines (AAM) has named Chirag Patel, Amneal Pharmaceuticals Inc’s (NYSE: AMRX) Co-Founder, President and Co-Chief Executive Officer, as its new Chairman.
Patel succeeds Alok Sonig, CEO, US Generics and Global Head, Generics R&D and Biosimilars of Lupin, Inc., as AAM Board of Directors Chairman.
The generic and biosimilar medicines industry continues to deliver so much good for so many people, filling more than 90% of all prescriptions in the United States while only contributing 18% of the total spend, said Patel.
As Board Chair, I am committed to working alongside my peers to meaningfully advance our critical work in providing safe, effective, reliable and affordable medicines to American patients.
I look forward to partnering with Chirag as he brings his unique passion and indefatigable energy to the position of chairman and leadership of the industry, said Dan Leonard, president and CEO of AAM.
AAM also named Christine Baeder, Teva Pharmaceuticals USA, Inc. Vice Chair of the Board and Terry Fullem, Jubilant Cadista Pharmaceuticals, Inc. as Treasurer. The full AAM Board of Directors can be found here.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 18 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.